Protalix BioTherapeutics, Inc. PLX
2.86 USD +0.29 (+11.28%)
At closeNov 11, 2026, 4:57 AM EST
2.51 -0.35 -12.24%
Pre-market · Nov 11, 4:57 AM ET
2.45 Day range 2.97
1.65 52-week range 3.19
- YTD
- +58.89%
- 1 year
- +34.27%
News
seekingalpha.com Protalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call Transcript Protalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call Transcript
benzinga.com Protalix BioTherapeutics Q3 2026 Earnings Call Transcript Protalix BioTherapeutics (AMEX:PLX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Protalix BioTherapeutics Affirms FY2026 Sales Guidance of $78.000M-$83.000M vs $71.359M Est Protalix BioTherapeutics (AMEX:PLX) affirms FY2026 sales outlook from $78.000 million-$83.000 million to $78.000 million-$83.000 million vs $71.359 million estimate.
prnewswire.com Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. ET Total revenues increased by $32.0 million year to date to $75.6 million, from $43.6 million for the same period in 2025 Net income…
globenewswire.com Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200 Boys Town National Research Hospital in Nebraska becomes first activated site in study targeting four rare pediatric lysosomal storage disorders and has now initiated patient screening as Polaryx…
benzinga.com Protalix Biotherapeutics To Present Individual Participant Results From PK And PD Analysis Of Higher-Dose Cohorts Of Its Phase 1 Single Ascending Dose Study Of PRX-115, At ACR Convergence 2026 Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled GoutThe Company previously reported that higher single doses of PRX–115…
prnewswire.com Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled Gout The Company previously reported that higher single doses of PRX–115…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…